Christie Ballantyne, a cardiologist at the Baylor College of Medicine, led a clinical trial that indicated Vytorin may have a potent anti-inflammatory effect.
In a statement handed out to reporters, Merck said that the class effect might extend beyond these Cox-2 inhibitors, to many older non-steroidal anti-inflammatory drugs.